Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1996-12-04
2000-11-28
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514177, 514912, A67K 3156
Patent
active
061536075
ABSTRACT:
A preservative-free composition containing an effective amount of a corticosteroid in an aqueous carrier to treat a dry eye condition. The composition may be provided as a part of a therapeutic regimen to treat a variety of dry eye conditions and ocular surface disorders manifesting delayed tear clearance previously not readily treatable. The composition may be packaged as containers of single dosage amounts of the corticosteroid-aqueous composition sufficient for pulsed-therapy of acute exacerbations of the irritation symptoms and ocular surface disease of conditions associated with dry eye and delayed tear clearance.
REFERENCES:
patent: Re34578 (1994-04-01), Lubkin
patent: 4304765 (1981-12-01), Shell et al.
patent: 4407792 (1983-10-01), Schoenwald et al.
patent: 4448774 (1984-05-01), Clemente et al.
patent: 4474751 (1984-10-01), Haslam et al.
patent: 5041434 (1991-08-01), Lubkin
patent: 5252318 (1993-10-01), Joshi et al.
patent: 5340572 (1994-08-01), Patel et al.
patent: 5620921 (1997-04-01), Sullivan
Holly FJ et al, Tear Physiology and dry eyes. Review. Survey Opthalmol. 1977; 22:69-87.
Holly FJ., Formation and stability of the tear film. Int. Ophthalmol. Clin. 1973; 13:73-96.
Murillo-Lopez et al, Dry Eyes in Cornea, Krachmer, Mannis, Holland (editors) St. Louis, Mosby, 1996 (Galley); Chapter 56 pp 663-686.
Pflugfelder et al. The autoimmune nature of aqueous tear deficiency; Ophthalmology 1986;93:1513-1517.
Pflugfelder et al, Conjunctival cytological features of primary Sjogren's Syndrome; Ophthalmology 1990;97:985-991.
Pflugfelder et al, B. Coorelation of conjunctival globlet cell...ocular irritation; Ophthalmology; Feb. 1997:223-235.
Hideji et al, Confocal microscopic studies . . . benzalkonium chloride. Comea. 1992; 11:221-225.
Ubels et al, Effects of preservative-free . . . epithelial structure and function. Arch Ophthalmol. 1995; 113:371-378.
Lee et sl, Glucocorticosteriods selectively inhibit . . . mRNA, Proc Natl Acad Sci USA 1988; 85:1204-8.
Zanler et al, Evidence tha glucocorticosteriods block . . . accessory cells; Transplantation 1990; 49:183-185.
Marron et al, Alterations in renal interleukin-1 . . . rejection in the rat; Transplantation 1993; 56:1157-1162.
Hall et al, Effects of Intravenous methylprednisolone . . . in the cat; J. Neurosurg 1982; 57:247-253.
Anderson et al, Lipid hydrolysis...selenium. CNS Trauma 1985; 2:257-267.
"Ocular Anti-Inflammatory Agents"; Pharmaceuticals; PDR for Ophthalmology.
Jones et al; Sjogren's Syndrome: "Cytokine and Opstein . . . Epithelium"; Investigative Ophthalmology & Visual Science, Aug. 1994, vol. 35, No. 9 p. 3493-3504.
Wright, "Filamentary Keratitis", Trans. Ophthal. Soc. UK (1975) 95, pp. 260-266.
Huang Andrew J. W.
Pflugfelder Stephen C.
Tseng Scheffer C. G.
Fay Zohreh
University of Miami
LandOfFree
Non-preserved topical corticosteroid for treatment of dry eye, f does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-preserved topical corticosteroid for treatment of dry eye, f, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-preserved topical corticosteroid for treatment of dry eye, f will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726022